News | June 07, 2010

St. Jude Pays $3.7 Million to Resolve Fraud Allegations

June 7, 2010 – St. Jude Medical and two hospitals agreed to pay $3.7 million to resolve allegations it paid illegal kickbacks to two hospitals to secure heart-device business, the Justice Department (DOJ) said. The government alleges the kickbacks caused false claims to be submitted to federal health care programs in violation of the False Claims Act.

The DOJ said kickbacks included alleged rebates that were retroactive and paid based on a hospital's previous purchases of St. Jude heart-device equipment. The DOJ also said St. Jude paid rebates for purchases of heart-device equipment sold by its competitors to induce purchases of similar equipment from St. Jude in the future.

St. Jude Medical said in a statement the agreement fully resolves the investigation. The company said the allegations centered on small, isolated product rebates that the company paid more than five years ago. St. Jude said it entered into a settlement agreement in order to avoid the potential costs and risks associated with litigation, but does not admit liability or wrongdoing.

Under the terms of the settlement, the company will pay $3.7 million. Parma Community General Hospital, located in Parma, Ohio, is paying $40,000, and Norton Healthcare in Louisville, Ky., is paying $133,300. The government asserted that Parma and Norton were recipients of the improper rebates from St. Jude.

"Hospitals should base their purchasing decisions on what is in the best interests of their patients," said Tony West, assistant attorney general for the civil division of the DOJ. "We will act aggressively to ensure that choices about health care are not tainted by illegal kickbacks."

This action was initiated by the filing of an action under the False Claims Act by an internal whistleblower, Jerry Hudson. Under the qui tam, or whistleblower, provisions of the act, private citizens may bring lawsuits on behalf of the United States and share in any recovery. Hudson's share of the settlement is $640,050.

"St. Jude's marketing strategy interfered with the doctors' independent decision making,” said Warner Mendenhall, Hudson’s attorney from McLaughlin and McCaffrey LLP. “These types of incentives to gain market share shortchange patient care options for doctors and patients alike. These incentives have more to do with sales than patient well-being."

The Complaint can be found at http://www.docstoc.com/docs/39559633/US-ex-rel-Hudson-v-St-Jude-Medical.

For more information: www.sjm.com, www.justice.gov/opa/pr/2010/June/10-civ-658.html

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init